Abstract
One third of patients with renal cell cancer have metastatic disease at diagnosis. Until now the outcome of these patients has been poor due to the variable natural history of the disease and the lack of effective therapy. Multitargeted therapy of advanced renal cell cancer appears to be a better option than immunotherapy. We report the case of an elderly patient with skin, lung, bone and brain metastases and widespread intraabdominal disease treated with cytoreductive surgery and sunitinib, resulting in a prolonged response.
MeSH terms
-
Aged
-
Antineoplastic Agents / therapeutic use*
-
Carcinoma, Renal Cell / drug therapy
-
Carcinoma, Renal Cell / secondary
-
Carcinoma, Renal Cell / surgery
-
Carcinoma, Renal Cell / therapy*
-
Chemotherapy, Adjuvant
-
Female
-
Humans
-
Indoles / therapeutic use*
-
Kidney Neoplasms / drug therapy
-
Kidney Neoplasms / pathology
-
Kidney Neoplasms / surgery
-
Kidney Neoplasms / therapy*
-
Neoplasms, Multiple Primary / diagnostic imaging
-
Neoplasms, Multiple Primary / drug therapy
-
Neoplasms, Multiple Primary / surgery
-
Neoplasms, Multiple Primary / therapy*
-
Nephrectomy*
-
Pyrroles / therapeutic use*
-
Sunitinib
-
Tomography, X-Ray Computed
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Indoles
-
Pyrroles
-
Sunitinib